Evercore ISI analyst Liisa Bayko raised the firm’s price target on Altimmune to $25 from $14 and keeps an Outperform rating on the shares. Bayko thinks the opportunity in NASH provides a solid second indication and downside protection, should the obesity data come shy of expectations, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on ALT:
- Cantor Fitzgerald biotech analyst to hold analyst/industry conference call
- Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023
- Altimmune Appoints Raymond Jordt as Chief Business Officer
- Altimmune appoints Jordt as Chief Business Officer
- Altimmune 24-week NAFLD data ‘strong and encouraging,’ says Piper Sandler
